A 52-week, randomized, double-blind, parallel-group study of fluticasone propionate/salmeterol DISKUS combination product (FSC) 250/50 mcg BID and fluticasone propionate (FP) DISKUS 250 mcg BID in treatment of subjects with asthma.

Trial Profile

A 52-week, randomized, double-blind, parallel-group study of fluticasone propionate/salmeterol DISKUS combination product (FSC) 250/50 mcg BID and fluticasone propionate (FP) DISKUS 250 mcg BID in treatment of subjects with asthma.

Completed
Phase of Trial: Phase IV

Latest Information Update: 27 Dec 2016

At a glance

  • Drugs Fluticasone propionate; Salmeterol/fluticasone propionate
  • Indications Asthma
  • Focus Therapeutic Use
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 27 Dec 2016 New source identified and integrated (European Clinical Trials Database record; EudraCT2015-004892-61).
    • 14 May 2010 Results presented at 106th International Conference of the American Thoracic Society.
    • 02 Mar 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top